aap: 47% First-Half Sales Growth to EUR 9.2m, Operating Result EUR 1.7m

aap Implantate AG, a medical technology company listed in the Prime Standard Segment on the Frankfurt Stock Exchange and active in the fields of biomaterials and implants for trauma and joint reconstruction, was able to boost sales in the second quarter of fiscal 2006 by 54% on the year to EUR 4.9 million (previous year: EUR 3.2 million). First-half sales growth was 47% to EUR 9.2 million (previous year: EUR 6.3 million).

For the first six months of the current financial year the aap Group posted an EBITDA of EUR 2.5 million (previous year: EUR 771K). The Group’s operating result (EBIT) improved in the first-half to EUR 1.7 million (previous year: EUR 83K). EBT in this period was EUR 1.7 million, or well above the previous year’s EUR minus 3K. After writing off deferred taxes carried as assets, the surplus for the first six months was EUR 1.0 million (previous year: EUR minus 146K).

With a EUR 25.6 million balance sheet total, the equity ratio was 82%.

Given aap’s positive first-half development, the Management Board has made a more detailed forecast for fiscal 2006. The company’s targets are year-on-year sales growth of between 30% and 40% (EUR 17.3 million to EUR 18.6 million) and earnings before taxes amounting to between 16% and 21% (EUR 2.7 million to EUR 3.9 million) of sales revenues.